Vera Salus Ricerca

Inocras Inc. (Inocras) ha chiuso un round di finanziamento di Series B‑3 da 31 milioni di dollari. Questi ulteriori fondi saranno impiegati da Inocras per espandere l’infrastruttura diagnostica oncologica certificata CLIA/CAP in US e le pipeline bioinformatiche automatizzate in Asia. Le piattaforme diagnostiche sono basate su soluzioni di whole-genomic sequencing (WGS) che includono profilazioni somatico/germinali e monitoraggio di minimal residual disease (MRD).
https://hitconsultant.net/2026/08/03/inocras-raises-31m-series-b3-funding-whole-genome-oncology/

A longitudinal clinical study published in 𝘊𝘢𝘯𝘤𝘦𝘳 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 demonstrates the diagnostic utility of serial genomic monitoring for the risk stratification and clinical management of patients with chronic blood neoplasms.
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-26-0410/787208/Genomic-Evolution-of-Myeloproliferative-Neoplasms

An experimenatl work published in the scientific journal 𝘕𝘢𝘵𝘶𝘳𝘦 demonstrates that the specific genetic background can influence both the occurrence and progression of cancer.
https://www.nature.com/articles/s41586-026-10821-z

Tempus AI ha raggiunto un accordo per l'acquisizione di Personalis a circa 1,5 miliardi di dollari. L’operazione fortifica la posizione commerciale di Tempus AI nell'ambito della diagnostica oncologica di MRD (malattia minima residua), attraverso l'integrazione della tecnologia di Personalis nelle piattaforme computazionali dell’azienda.
https://finance.yahoo.com/healthcare/articles/tempus-ai-tem-buying-personalis-091037787.html

A research work published in 𝘕𝘢𝘵𝘶𝘳𝘦 demonstrates that enterotoxigenic 𝘉𝘢𝘤𝘵𝘦𝘳𝘰𝘪𝘥𝘦𝘴 𝘧𝘳𝘢𝘨𝘪𝘭𝘪𝘴 (𝘉. 𝘧𝘳𝘢𝘨𝘪𝘭𝘪𝘴) promotes colorectal carcinogenesis (CRC) by targeting claudin-4, expressed in intestinal epithelial cells, and cleaving E-cadherin through the 𝘉. 𝘧𝘳𝘢𝘨𝘪𝘭𝘪𝘴 toxin (BFT).
https://www.nature.com/articles/s41586-026-10375-0

A research work published in the 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘢𝘭 𝘊𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 reports on a novel PAK1/HDAC10 dual inhibitor that efficiently inhibits cancer growth and metastasis, while promoting antitumor immunity in triple-negative breast cancer (TNBC).
https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00487

Biocartis e Discovery Life Sciences (Discovery) hanno avviato una collaborazione strategica globale per integrare la piattaforma PCR automatizzata 𝘐𝘥𝘺𝘭𝘭𝘢 (di Biocartis) con la rete laboratoristica di Discovery, offrendo soluzioni end‑to‑end per la diagnostica di precisione in oncologia (onco-Dx). La partnership punta a velocizzare i test diagnostici (dx) e la conduzione dei trial clinici.
https://www.biospace.com/press-releases/press-release-biocartis-nv-biocartis-and-discovery-life-sciences-announce-strategic-collaboration-to-advance-precision-oncology-diagnostics

A research study published in 𝘊𝘦𝘭𝘭 demonstrates the efficacy and scalability of a new anticancer cell system for chimeric antigen receptor (CAR) therapy, represented by granulocyte-monocyte progenitors (GMPs).
https://www.cell.com/cell/fulltext/S0092-8674(26)00643-4

AbbVie ha acquisito Apogee Therapeutics (Apogee) ed il suo anticorpo anti‑interleuchina 13 (IL13) zumilokibart per 10,9 miliardi di dollari. Zumilokibart presenta una superiorità competitiva legata alla posologia favorevole, e si trova attualmente in Fase 2 di sviluppo clinico per la cura dei pazienti con eczema.
https://www.fiercebiotech.com/biotech/abbvie-inks-109b-apogee-buyout-bag-hotly-tipped-eczema-prospect

A reserach study published in the journal Nature describes the occurrence of heavy DNA double-strand break events during cerebral cortex development. In particular, nuclei of migrating neurons undergo elevated mechanostress resulting in diffuse DNA damage that, if unrepaired, may cause pathological dysfunctions later in life.
https://www.nature.com/articles/s41586-026-10648-8